Krilogy Financial’s Lexicon Pharmaceuticals LXRX Stock Holding History

Krilogy Financial’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-500	Closed	-$5K	–	448
2018 Q3	$5K	Buy	+500	New	+$5.73K	﹤0.01%	623
2018 Q2	–	Sell	-500	Closed	-$4K	–	427
2018 Q1	$4K	Hold	500	–	–	﹤0.01%	627
2017 Q4	$5K	Sell	500 -300	-38%	-$3.12K	﹤0.01%	600
2017 Q3	$10K	Hold	800	–	–	﹤0.01%	580
2017 Q2	$13K	Hold	800	–	–	﹤0.01%	500
2017 Q1	$11K	Hold	800	–	–	﹤0.01%	503
2016 Q4	$11K	Hold	800	–	–	﹤0.01%	503
2016 Q3	$14K	Sell	800 -175	-18%	-$2.82K	﹤0.01%	484
2016 Q2	$14K	Buy	975 +675	+225%	+$9.15K	﹤0.01%	484
2016 Q1	$4K	Buy	+300	New	+$3.15K	﹤0.01%	555
2015 Q4	–	Sell	-300	Closed	-$3K	–	536
2015 Q3	$3K	Buy	+300	New	+$3.28K	﹤0.01%	515

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

SGA

Sector Gamma AS Oslo, Norway $461M AUM 33.26% 1-Year Est. Return

Krilogy Financial's LXRX Position: Q4 2018 in Review

Krilogy Financial sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2018, closing a stake of 500 shares — an estimated $5K sold.

Krilogy Financial first reported a position in LXRX in Q3 2015 and held it in 11 quarters. The position peaked at $14K in Q3 2016. 122 funds tracked by Wall St. Rank hold LXRX as of Q4 2018.

Krilogy Financial reported no remaining Lexicon Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Krilogy Financial sold 500 Lexicon Pharmaceuticals shares in Q4 2018, an estimated $5K.
Krilogy Financial first reported a position in Lexicon Pharmaceuticals in Q3 2015 and held it in 11 quarters.
Krilogy Financial's Lexicon Pharmaceuticals position peaked at $14K in Q3 2016.
122 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.